Effect group in full replicate Bioequivalence [Study Per­for­mance]

posted by Laura Carreiras – Portugal, 2022-05-11 15:11 (271 d 16:53 ago) – Posting: # 22969
Views: 715

Dears,

In a in a bioequivalence study with a full replicate design conducted in more than one group, how shall the group participants be separated/divided?

For example,

Initially we have 3 groups but because of some constraints the washouts for a few participants had to be extended.

The participants will be added to the groups accordingly with the administration date of the first period (even if the other periods can have a different administration date) or the groups shall be formed accordingly with the date of administration of all the periods (for each group all the administration date of the 4 periods has to be the same)?


I hope I was clear.

Thank you for the help.


Edit: Category changed; see also this post #1[Helmut]

Complete thread:

UA Flag
Activity
 Admin contact
22,481 posts in 4,710 threads, 1,603 registered users;
23 visitors (0 registered, 23 guests [including 11 identified bots]).
Forum time: 07:05 CET (Europe/Vienna)

The difference between a surrogate and a true endpoint
is like the difference between a cheque and cash.
You can get the cheque earlier but then,
of course, it might bounce.    Stephen Senn

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5